Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

346 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
BRAF mutation predicts sensitivity to MEK inhibition.
Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N. Solit DB, et al. Among authors: osman i. Nature. 2006 Jan 19;439(7074):358-62. doi: 10.1038/nature04304. Epub 2005 Nov 6. Nature. 2006. PMID: 16273091 Free PMC article.
BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
Paoluzzi L, Hanniford D, Sokolova E, Osman I, Darvishian F, Wang J, Bradner JE, Hernando E. Paoluzzi L, et al. Among authors: osman i. Cancer Med. 2016 Jun;5(6):1183-93. doi: 10.1002/cam4.667. Epub 2016 May 11. Cancer Med. 2016. PMID: 27169980 Free PMC article.
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8.
Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, Segura MF, Emanuel PO, Menendez S, Vardabasso C, Leroy G, Vidal CI, Polsky D, Osman I, Garcia BA, Hernando E, Bernstein E. Kapoor A, et al. Among authors: osman i. Nature. 2010 Dec 23;468(7327):1105-9. doi: 10.1038/nature09590. Nature. 2010. PMID: 21179167 Free PMC article.
FBXW7 modulates cellular stress response and metastatic potential through ​HSF1 post-translational modification.
Kourtis N, Moubarak RS, Aranda-Orgilles B, Lui K, Aydin IT, Trimarchi T, Darvishian F, Salvaggio C, Zhong J, Bhatt K, Chen EI, Celebi JT, Lazaris C, Tsirigos A, Osman I, Hernando E, Aifantis I. Kourtis N, et al. Among authors: osman i. Nat Cell Biol. 2015 Mar;17(3):322-332. doi: 10.1038/ncb3121. Nat Cell Biol. 2015. PMID: 25720964 Free PMC article.
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. Lin L, et al. Among authors: osman i. Nat Genet. 2015 Mar;47(3):250-6. doi: 10.1038/ng.3218. Epub 2015 Feb 9. Nat Genet. 2015. PMID: 25665005 Free PMC article.
A phase II trial of sorafenib in metastatic melanoma with tissue correlates.
Ott PA, Hamilton A, Min C, Safarzadeh-Amiri S, Goldberg L, Yoon J, Yee H, Buckley M, Christos PJ, Wright JJ, Polsky D, Osman I, Liebes L, Pavlick AC. Ott PA, et al. Among authors: osman i. PLoS One. 2010 Dec 29;5(12):e15588. doi: 10.1371/journal.pone.0015588. PLoS One. 2010. PMID: 21206909 Free PMC article. Clinical Trial.
346 results